Bedeutung des C-reaktiven Proteins im Rahmen maligner ...

64
84. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of
total and HDL cholesterol in determining risk of first myocardial infarction. Circulation
1998;97:2007-2011
85. Ridker PM, Rifai N, Pfeffer MA et al. Long-term effects of pravastatin on plasma
concentration of C-reactive protein: the Cholesterol and Recurrent Events (CARE)
Investigators. Circulation 1999;100:230-235
86. Ridker PM, Rifai N, Clearfield M et al. Measurement of C-reactive protein for the
targeting of statin therapy in the primary prevention of acute coronary events. N Engl J
Med 2001;344:1959-1965
87. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with
cerivastatin among 785 patients with primary hypercholesterolemia. Circulation
2001;103:1191-1193
88. Robey FA, Jones KD. C-reactive protein, chromatin, immunomodulation and the acute
phase response: In vitro evidence for a possible "CRP cycle". Prot Biol Fluids
1986;34:267-270
89. Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal
cell carcinoma. J Urol 1969;101:297
90. Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999;340:115-126
91. Sandler RS, Halabi S, Baron JA et al. A randomized trial of aspirin to prevent colorectal
adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-890
92. Schafhauser W, Ebert A, Brod J, Petsch S, Schrott KM. Lymph node in volvement in
renal cell carcinoma and survival chance by systematic lymphadenectomy. Anticanver
Res 1999;19:1573-1578
93. Szalai A. C-reactive protein (CRP) and autoimmune disease: facts and conjectures. Clin
Dev Immunol 2004;11:221-226
94. Takenava J, Kaneko Y, Fukumoto M, Fukatsu A, Hirano T, Fukuyama H, Nakayama H,
Fujita J, Yoshida O. Enhanced expression of interleukin-6 in primary human renal cell
carcinomas. J Natl Cancer Inst 1991;83:1668-1672
95. Tartour E, Dorval T, Mosseri V et al. Serum interleukin 6 and C-reactive protein levels
correlate with resistence to IL-2 therapy and poor survival in melanoma patients. Br J
Cancer 1994;69:911-913
96. Terada K, Hayashi G, Hokama Y. C-reactive protein and 6-Keto Prostaglandin F 1-α in
patients with gynecologic cancer. Gynecol Oncol 1990;36:212-214
97. Thoenes W, Störkel S, Rumpelt HJ. Histology and classification of renal cell tumors
(adenomas, oncocytomas, and carcinomas): the basic cytological and histological
elements and their use for diagnostics. Path Res Pract 1986;181:125-143